ArticlePloS one2025
The association between circadian syndrome and possible sarcopenia in an aging population: A 4-year follow-up study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between relative muscle strength and circadian syndrome among middle-aged and older Chinese adults.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRecently, circadian syndrome (CircS) is proposed as a novel risk cluster based on sleep disorder, depression, dyslipidemia, hyperglycemia, hypertension and abdominal obesity. To investigate the association between CircS and possible sarcopenia, this study was performed.
methodsPossible sarcopenia is defined according to Asian Working Group for Sarcopenia in 2019, which includes measures of muscle strength and physical performance. In the baseline survey, 7,905 participants aged ≥ 40 years from the China Health and Retirement Longitudinal Study were included. Multivariate logistic regression was used to evaluate the association between CircS and possible sarcopenia. Subgroup and interactive analyses were adopted to verify the findings in the overall population and identify potential interactive effects. The obese population was excluded and the missing values were interpolated using multivariate imputation by chained equations as sensitivity analyses. In addition, the participants were followed up for four years to explore the longitudinal association between CircS and incident possible sarcopenia.
resultsAs per one increase of CircS components, participants had a 1.11-fold (95% CI = 1.07-1.14, P < 0.001) risk of prevalent possible sarcopenia in the full model. The CircS group was associated with a 1.30-fold (95% CI = 1.17-1.44) risk of prevalent possible sarcopenia (P < 0.001). No significant interactive effects of covariates on the association between CircS and prevalent possible sarcopenia were detected (all P for interaction > 0.05). All the subgroup and sensitivity analyses supported the positive association between CircS and possible sarcopenia. In the longitudinal follow-up, the odd ratio was 1.06 (95% CI = 1.00-1.13, P < 0.05) as per one increase of CircS components in the full model. The CircS group was also found to have an elevated risk of incident possible sarcopenia (odd ratio = 1.24, 95% CI = 1.03-1.50, P < 0.05) after adjusting all the covariates.
conclusionsCircS is a risk factor for possible sarcopenia, which may serve as a predictor of possible sarcopenia for early identification and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.